Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

The Undiscovered Potential of Essential Oils for Treating SARS-CoV-2 (COVID-19)

Author(s): Peter J. Wilkin, Minnatallah Al-Yozbaki, Alex George, Girish K. Gupta and Cornelia M. Wilson*

Volume 26, Issue 41, 2020

Page: [5261 - 5277] Pages: 17

DOI: 10.2174/1381612826666201015154611

Price: $65

Abstract

On 11th March 2020, the World Health Organisation (WHO) announced a pandemic caused by a novel beta-coronavirus SARS-CoV-2, designated COVID-19. The virus emerged in December 2019 in Wuhan, China, has spread across the world as a global pandemic. The traditional use of medicines from plants can be traced back to 60,000 years. Global interest in the development of drugs from natural products has increased greatly during the last few decades. Essential oils (EOs) have been studied through the centuries and are known to possess various pharmaceutical properties. In the present review, we have highlighted the current biology, epidemiology, various clinical aspects, different diagnostic techniques, clinical symptoms, and management of COVID-19. An overview of the antiviral action of EOs, along with their proposed mechanism of action and in silico studies conducted, is described. The reported studies of EOs' antiviral activity highlight the baseline data about the additive and/or synergistic effects among primary or secondary phytoconstituents found in individual oils, combinations or blends of oils and between EOs and antiviral drugs. It is hoped that further research will provide better insights into EOs' potential to limit viral infection and aid in providing solutions through natural, therapeutically active agents.

Keywords: Coronavirus, COVID-19, SARS-CoV-2, essential oils, natural compounds, antiviral, anti-inflammation, mechanism of action.

« Previous Next »
[1]
WHO. Naming the coronavirus disease (COVID-19) and the virus that causes it. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it
[2]
Poutanen SM, Low DE, Henry B, et al. National Microbiology Laboratory, Canada; Canadian Severe Acute Respiratory Syndrome Study Team. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003; 348(20): 1995-2005.
[http://dx.doi.org/10.1056/NEJMoa030634] [PMID: 12671061]
[3]
Sharifi-Rad J, Sureda A, Tenore GC, et al. Biological Activities of Essential Oils: From Plant Chemoecology to Traditional Healing Systems. Molecules 2017; 22(1): 22.
[http://dx.doi.org/10.3390/molecules22010070] [PMID: 28045446]
[4]
Mérillon J-M, Rivière C. Natural Antimicrobial Agents. Switzerland: Springer International Publishing AG 2018.
[http://dx.doi.org/10.1007/978-3-319-67045-4]
[5]
Swamy MK, Sinniah UR. A Comprehensive Review on the Phytochemical Constituents and Pharmacological Activities of Pogostemon cablin Benth.: An Aromatic Medicinal Plant of Industrial Importance. Molecules 2015; 20(5): 8521-47.
[http://dx.doi.org/10.3390/molecules20058521] [PMID: 25985355]
[6]
Yuan H, Ma Q, Ye L, Piao G. The Traditional Medicine and Modern Medicine from Natural Products. Molecules 2016; 21(5): 21.
[http://dx.doi.org/10.3390/molecules21050559] [PMID: 27136524]
[7]
Wani MC, Horwitz SB. Nature as a remarkable chemist: a personal story of the discovery and development of Taxol. Anticancer Drugs 2014; 25(5): 482-7.
[http://dx.doi.org/10.1097/CAD.0000000000000063] [PMID: 24413390]
[8]
Silva J, Abebe W, Sousa SM, Duarte VG, Machado MI, Matos FJ. Analgesic and anti-inflammatory effects of essential oils of Eucalyptus. J Ethnopharmacol 2003; 89(2-3): 277-83.
[http://dx.doi.org/10.1016/j.jep.2003.09.007] [PMID: 14611892]
[9]
Randall JP, Seow WK, Walsh LJ. Antibacterial activity of fluoride compounds and herbal toothpastes on Streptococcus mutans: an in vitro study. Aust Dent J 2015; 60(3): 368-74.
[http://dx.doi.org/10.1111/adj.12247] [PMID: 25348354]
[10]
Karadağlıoğlu Öİ, Ulusoy N, Başer KHC, Hanoğlu A, Şık İ. Antibacterial Activities of Herbal Toothpastes Combined with Essential Oils against Streptococcus mutans. Pathogens 2019; 8(1): 8.
[http://dx.doi.org/10.3390/pathogens8010020] [PMID: 30717107]
[11]
Liu GT. Bicyclol: a novel drug for treating chronic viral hepatitis B and C. Med Chem 2009; 5(1): 29-43.
[http://dx.doi.org/10.2174/157340609787049316] [PMID: 19149648]
[12]
Raut JS, Karuppayil SM. A status review on the medicinal properties of essential oils. Ind Crops Prod 2014; 62: 250-64.
[http://dx.doi.org/10.1016/j.indcrop.2014.05.055]
[13]
Swamy MK, Akhtar MS, Sinniah UR. Antimicrobial Properties of Plant Essential Oils against Human Pathogens and Their Mode of Action: An Updated Review. Evid Based Complement Alternat Med 2016.20163012462
[http://dx.doi.org/10.1155/2016/3012462] [PMID: 28090211]
[14]
Zumla A, Chan JFW, Azhar EI, Hui DSC, Yuen K-Y. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov 2016; 15(5): 327-47.
[http://dx.doi.org/10.1038/nrd.2015.37] [PMID: 26868298]
[15]
Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019; 17(3): 181-92.
[http://dx.doi.org/10.1038/s41579-018-0118-9] [PMID: 30531947]
[16]
Forni D, Cagliani R, Clerici M, Sironi M. Molecular Evolution of Human Coronavirus Genomes. Trends Microbiol 2017; 25(1): 35-48.
[http://dx.doi.org/10.1016/j.tim.2016.09.001] [PMID: 27743750]
[17]
Su S, Wong G, Shi W, et al. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends Microbiol 2016; 24(6): 490-502.
[http://dx.doi.org/10.1016/j.tim.2016.03.003] [PMID: 27012512]
[18]
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054-62.
[http://dx.doi.org/10.1016/S0140-6736(20)30566-3] [PMID: 32171076]
[19]
Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 2015; 1282: 1-23.
[http://dx.doi.org/10.1007/978-1-4939-2438-7_1] [PMID: 25720466]
[20]
Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020; 367(6483): 1260-3.
[http://dx.doi.org/10.1126/science.abb2507] [PMID: 32075877]
[21]
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 2020; 181(2): 281-292.e6.
[http://dx.doi.org/10.1016/j.cell.2020.02.058] [PMID: 32155444]
[22]
Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology 2018; 23(2): 130-7.
[http://dx.doi.org/10.1111/resp.13196] [PMID: 29052924]
[23]
Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798): 270-3.
[http://dx.doi.org/10.1038/s41586-020-2012-7] [PMID: 32015507]
[24]
Giovanetti M, Benvenuto D, Angeletti S, Ciccozzi M. The first two cases of 2019-nCoV in Italy: Where they come from? J Med Virol 2020; 92(5): 518-21.
[http://dx.doi.org/10.1002/jmv.25699] [PMID: 32022275]
[25]
Paraskevis D, Kostaki EG, Magiorkinis G, Panayiotakopoulos G, Sourvinos G, Tsiodras S. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect Genet Evol 2020.79104212
[http://dx.doi.org/10.1016/j.meegid.2020.104212] [PMID: 32004758]
[26]
Banerjee A, Kulcsar K, Misra V, Frieman M, Mossman K. Bats and Coronaviruses. Viruses 2019; 11(1): 11.
[http://dx.doi.org/10.3390/v11010041] [PMID: 30634396]
[27]
Li W, Shi Z, Yu M, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 2005; 310(5748): 676-9.
[http://dx.doi.org/10.1126/science.1118391] [PMID: 16195424]
[28]
Hampton T. Bats may be SARS reservoir. JAMA 2005; 294(18): 2291.
[http://dx.doi.org/10.1001/jama.294.18.2291] [PMID: 16278351]
[29]
Guan WJ, Ni ZY, Hu Y, et al. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20.
[http://dx.doi.org/10.1056/NEJMoa2002032] [PMID: 32109013]
[30]
Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 2020; 382(13): 1199-207.
[http://dx.doi.org/10.1056/NEJMoa2001316] [PMID: 31995857]
[31]
Lee PI, Hsueh PR. Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV. J Microbiol Immunol Infect 2020; 53(3): 365-7.
[http://dx.doi.org/10.1016/j.jmii.2020.02.001] [PMID: 32035811]
[32]
Zhang W, Du RH, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect 2020; 9(1): 386-9.
[http://dx.doi.org/10.1080/22221751.2020.1729071] [PMID: 32065057]
[33]
Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004; 203(2): 631-7.
[http://dx.doi.org/10.1002/path.1570] [PMID: 15141377]
[34]
Jin YH, Cai L, Cheng ZS, et al. for the Zhongnan Hospital of Wuhan University Novel Coronavirus Management and Research Team, Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM). A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 2020; 7(1): 4.
[http://dx.doi.org/10.1186/s40779-020-0233-6] [PMID: 32029004]
[35]
Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061-9.
[http://dx.doi.org/10.1001/jama.2020.1585] [PMID: 32031570]
[36]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[37]
Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol 2020; 92(4): 401-2.
[http://dx.doi.org/10.1002/jmv.25678] [PMID: 31950516]
[38]
Chung M, Bernheim A, Mei X, et al. CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV). Radiology 2020; 295(1): 202-7.
[http://dx.doi.org/10.1148/radiol.2020200230] [PMID: 32017661]
[39]
Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020; 25(3): 25.
[http://dx.doi.org/10.2807/1560-7917.ES.2020.25.3.2000045] [PMID: 31992387]
[40]
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507-13.
[http://dx.doi.org/10.1016/S0140-6736(20)30211-7] [PMID: 32007143]
[41]
Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348(20): 1986-94.
[http://dx.doi.org/10.1056/NEJMoa030685] [PMID: 12682352]
[42]
Wang H, Xiao X, Lu J, et al. Factors associated with clinical outcome in 25 patients with avian influenza A (H7N9) infection in Guangzhou, China. BMC Infect Dis 2016; 16(1): 534.
[http://dx.doi.org/10.1186/s12879-016-1840-4] [PMID: 27716101]
[43]
Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013; 13(9): 752-61.
[http://dx.doi.org/10.1016/S1473-3099(13)70204-4] [PMID: 23891402]
[44]
Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl) 2020; 133(9): 1025-31.
[http://dx.doi.org/10.1097/CM9.0000000000000744] [PMID: 32044814]
[45]
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. HLH Across Speciality Collaboration. UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395(10229): 1033-4.
[http://dx.doi.org/10.1016/S0140-6736(20)30628-0] [PMID: 32192578]
[46]
WHO. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance. Available at: https://www.who.int/publications/i/item/clinical-management-of-covid-19
[47]
FDA. Enforcement Policy for Extracorporeal Membrane Oxygenation and Cardiopulmonary Bypass Devices During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency. The US Food and Drug Administration 2020.
[48]
Ahn JY, Sohn Y, Lee SH, et al. Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea. J Korean Med Sci 2020; 35(14)e149
[http://dx.doi.org/10.3346/jkms.2020.35.e149] [PMID: 32281317]
[49]
Zhang B, Liu S, Tan T, et al. Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Chest 2020; 158(1): e9-e13.
[http://dx.doi.org/10.1016/j.chest.2020.03.039] [PMID: 32243945]
[50]
Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA 2020; 323(16): 1582-9.
[http://dx.doi.org/10.1001/jama.2020.4783] [PMID: 32219428]
[51]
Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA 2020; 117(17): 9490-6.
[http://dx.doi.org/10.1073/pnas.2004168117] [PMID: 32253318]
[52]
Agostini ML, Andres EL, Sims AC, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. MBio 2018; 9(2): 9.
[http://dx.doi.org/10.1128/mBio.00221-18] [PMID: 29511076]
[53]
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-71.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[54]
Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020; 11(1): 222.
[http://dx.doi.org/10.1038/s41467-019-13940-6] [PMID: 31924756]
[55]
Holshue ML, DeBolt C, Lindquist S, et al. Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med 2020; 382(10): 929-36.
[http://dx.doi.org/10.1056/NEJMoa2001191] [PMID: 32004427]
[56]
US National Library Of Medicine. Available at: https://www.clinicaltrials.gov
[57]
Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis 2003; 3(11): 722-7.
[http://dx.doi.org/10.1016/S1473-3099(03)00806-5] [PMID: 14592603]
[58]
Aguiar ACC, Murce E, Cortopassi WA, et al. Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity. Int J Parasitol Drugs Drug Resist 2018; 8(3): 459-64.
[http://dx.doi.org/10.1016/j.ijpddr.2018.10.002] [PMID: 30396013]
[59]
Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005; 2: 69.
[http://dx.doi.org/10.1186/1743-422X-2-69] [PMID: 16115318]
[60]
Golden EB, Cho HY, Hofman FM, Louie SG, Schönthal AH, Chen TC. Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors. Neurosurg Focus 2015; 38(3)E12
[http://dx.doi.org/10.3171/2014.12.FOCUS14748] [PMID: 25727221]
[61]
Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother 2020; 75(7): 1667-70.
[http://dx.doi.org/10.1093/jac/dkaa114] [PMID: 32196083]
[62]
Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 2020; 55(5)105938
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105938] [PMID: 32171740]
[63]
Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; 71(15): 732-9.
[http://dx.doi.org/10.1093/cid/ciaa237] [PMID: 32150618]
[64]
Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003; 63(8): 769-802.
[http://dx.doi.org/10.2165/00003495-200363080-00004] [PMID: 12662125]
[65]
Arabi YM, Asiri AY, Assiri AM, et al. and the Saudi Critical Care Trials group. Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. Trials 2020; 21(1): 8.
[http://dx.doi.org/10.1186/s13063-019-3846-x] [PMID: 31900204]
[66]
Chu CM, Cheng VC, Hung IF, et al. HKU/UCH SARS Study Group. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004; 59(3): 252-6.
[http://dx.doi.org/10.1136/thorax.2003.012658] [PMID: 14985565]
[67]
Lim J, Jeon S, Shin HY, et al. Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR. J Korean Med Sci 2020; 35(6)e79
[http://dx.doi.org/10.3346/jkms.2020.35.e79] [PMID: 32056407]
[68]
Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 2020; 382(19): 1787-99.
[http://dx.doi.org/10.1056/NEJMoa2001282] [PMID: 32187464]
[69]
Srinivasa A, Tosounidou S, Gordon C. Increased Incidence of Gastrointestinal Side Effects in Patients Taking Hydroxychloroquine: A Brand-related Issue? J Rheumatol 2017; 44(3): 398.
[http://dx.doi.org/10.3899/jrheum.161063] [PMID: 28250164]
[70]
Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 2004; 136(1): 95-103.
[http://dx.doi.org/10.1111/j.1365-2249.2004.02415.x] [PMID: 15030519]
[71]
Faure E, Poissy J, Goffard A, et al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? PLoS One 2014; 9(2)e88716
[http://dx.doi.org/10.1371/journal.pone.0088716] [PMID: 24551142]
[72]
Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med 2006; 3(9)e343
[http://dx.doi.org/10.1371/journal.pmed.0030343] [PMID: 16968120]
[73]
Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; 395(10223): 473-5.
[http://dx.doi.org/10.1016/S0140-6736(20)30317-2] [PMID: 32043983]
[74]
Qiao W, Wang C, Chen B, et al. Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats. Cardiology 2015; 131(2): 97-106.
[http://dx.doi.org/10.1159/000375362] [PMID: 25896805]
[75]
Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020; 46(4): 586-90.
[http://dx.doi.org/10.1007/s00134-020-05985-9] [PMID: 32125455]
[76]
Hofmann H, Geier M, Marzi A, et al. Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor. Biochem Biophys Res Commun 2004; 319(4): 1216-21.
[http://dx.doi.org/10.1016/j.bbrc.2004.05.114] [PMID: 15194496]
[77]
Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ 2020; 27(5): 1451-4.
[http://dx.doi.org/10.1038/s41418-020-0530-3] [PMID: 32205856]
[78]
Yang Y, Islam MS, Wang J, Li Y, Chen X. Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective. Int J Biol Sci 2020; 16(10): 1708-17.
[http://dx.doi.org/10.7150/ijbs.45538] [PMID: 32226288]
[79]
Tariq S, Wani S, Rasool W, et al. A comprehensive review of the antibacterial, antifungal and antiviral potential of essential oils and their chemical constituents against drug-resistant microbial pathogens. Microb Pathog 2019.134103580
[http://dx.doi.org/10.1016/j.micpath.2019.103580] [PMID: 31195112]
[80]
Wińska K, Mączka W, Łyczko J, Grabarczyk M, Czubaszek A, Szumny A. Essential Oils as Antimicrobial Agents-Myth or Real Alternative? Molecules 2019; 24(11): 24.
[PMID: 31195752]
[81]
Maver T, Kurecic M, Smrke D, Stana-Kleinschek K, Maver U. Plant-Derived Medicines with Potential Use in Wound Treatment 2019.
[http://dx.doi.org/10.5772/intechopen.72813]
[82]
Yadav N, Chandra H. Suppression of inflammatory and infection responses in lung macrophages by eucalyptus oil and its constituent 1,8-cineole: Role of pattern recognition receptors TREM-1 and NLRP3, the MAP kinase regulator MKP-1, and NFκB. PLoS One 2017; 12(11)e0188232
[http://dx.doi.org/10.1371/journal.pone.0188232] [PMID: 29141025]
[83]
Horváth G, Ács K. Essential oils in the treatment of respiratory tract diseases highlighting their role in bacterial infections and their anti-inflammatory action: a review. Flavour Fragrance J 2015; 30(5): 331-41.
[http://dx.doi.org/10.1002/ffj.3252] [PMID: 32313366]
[84]
Erdogan OI, Özçelik B, Kartal M, Kan Y. Antimicrobial and antiviral effects of essential oils from selected Umbelliferae and Labiatae plants and individual essential oil components. Turk J Biol 2012; 36: 239-46.
[85]
Mani JS, Johnson JB, Steel JC, et al. Natural product-derived phytochemicals as potential agents against coronaviruses: A review. Virus Res 2020.284197989
[http://dx.doi.org/10.1016/j.virusres.2020.197989] [PMID: 32360300]
[86]
Chouhan S, Sharma K, Guleria S. Antimicrobial Activity of Some Essential Oils-Present Status and Future Perspectives. Medicines (Basel) 2017; 4(3): 4.
[PMID: 28930272]
[87]
Jamalipour Soufi G, Hekmatnia A, Nasrollahzadeh M, et al. SARS-CoV-2 (COVID-19): New Discoveries and Current Challenges. Appl Sci (Basel) 2020; 10: 3641.
[http://dx.doi.org/10.3390/app10103641]
[88]
Dhifi W, Bellili S, Jazi S, Bahloul N, Mnif W. Essential Oils’ Chemical Characterization and Investigation of Some Biological Activities: A Critical Review. Medicines (Basel) 2016; 3(4): 3.
[http://dx.doi.org/10.3390/medicines3040025] [PMID: 28930135]
[89]
Elyemni M, Louaste B, Nechad I, et al. Extraction of Essential Oils of Rosmarinus officinalis L. by Two Different Methods: Hydrodistillation and Microwave Assisted Hydrodistillation. ScientificWorldJournal 2019.20193659432
[http://dx.doi.org/10.1155/2019/3659432] [PMID: 31057339]
[90]
Danh L, Han L, Triet N, Zhao J, Mammucari R, Foster N. Comparison of Chemical Composition, Antioxidant and Antimicrobial Activity of Lavender (Lavandula angustifolia L.) Essential Oils Extracted by Supercritical CO2, Hexane and Hydrodistillation. Food Bioprocess Technol 2013; 6: 3481-9.
[http://dx.doi.org/10.1007/s11947-012-1026-z]
[91]
da Silveira e Sá RdeC. Andrade LN, de Sousa DP. Sesquiterpenes from Essential Oils and Anti-Inflammatory Activity. Nat Prod Commun 2015; 10(10): 1767-74.
[http://dx.doi.org/10.1177/1934578X1501001033] [PMID: 26669122]
[92]
Worth H, Schacher C, Dethlefsen U. Concomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: a placebo-controlled double-blind trial. Respir Res 2009; 10: 69.
[http://dx.doi.org/10.1186/1465-9921-10-69] [PMID: 19624838]
[93]
Fischer J, Dethlefsen U. Efficacy of cineole in patients suffering from acute bronchitis: a placebo-controlled double-blind trial. Cough 2013; 9(1): 25-5.
[http://dx.doi.org/10.1186/1745-9974-9-25] [PMID: 24261680]
[94]
Lane T, Anantpadma M, Freundlich JS, Davey RA, Madrid PB, Ekins S. The Natural Product Eugenol Is an Inhibitor of the Ebola Virus In Vitro. Pharm Res 2019; 36(7): 104-4.
[http://dx.doi.org/10.1007/s11095-019-2629-0] [PMID: 31101988]
[95]
Singh O, Khanam Z, Misra N, Srivastava MK. Chamomile (Matricaria chamomilla L.): An overview. Pharmacogn Rev 2011; 5(9): 82-95.
[http://dx.doi.org/10.4103/0973-7847.79103] [PMID: 22096322]
[96]
Thuy BTP, My TTA, Hai NTT, et al. Investigation into SARS-CoV-2 Resistance of Compounds in Garlic Essential Oil. ACS Omega 2020; 5(14): 8312-20.
[http://dx.doi.org/10.1021/acsomega.0c00772] [PMID: 32363255]
[97]
Abdelli I, Hassani F, Bekkel Brikci S, Ghalem S. In silico study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from Western Algeria. J Biomol Struct Dyn 2020; 1-14. Available at: https://www.tandfonline.com/doi/full/10.1080/07391102.2020.1763199
[PMID: 32362217]
[98]
Sharma AD. Eucalyptol (1,8 cineole) from Eucalyptus Essential Oil a Potential Inhibitor of COVID 19 Corona Virus Infection by Molecular Docking Studies 2020.
[99]
Silva JKRd. Figueiredo PLB, Byler KG, Setzer WN. Essential Oils as Antiviral Agents. Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation. Int J Mol Sci 2020; 21(10): 3426.
[100]
Luo P, Liu D, Li J. Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19. Int J Antimicrob Agents 2020; 55(6)105995
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105995] [PMID: 32335281]
[101]
Elfiky AA. Natural products may interfere with SARS-CoV-2 attachment to the host cell. J Biomol Struct Dyn 2020. In press
[PMID: 32340551]
[102]
Orsavova J, Misurcova L, Ambrozova JV, Vicha R, Mlcek J. Fatty Acids Composition of Vegetable Oils and Its Contribution to Dietary Energy Intake and Dependence of Cardiovascular Mortality on Dietary Intake of Fatty Acids. Int J Mol Sci 2015; 16(6): 12871-90.
[http://dx.doi.org/10.3390/ijms160612871] [PMID: 26057750]
[103]
Bourgou S, Tammar S, Salem N, Mkadmini K, Msaada K. Phenolic Composition, Essential Oil, and Antioxidant Activity in the Aerial Part of Artemisia Herba-Alba from Several Provenances: A Comparative Study. Int J Food Prop 2016; 19: 549-63.
[http://dx.doi.org/10.1080/10942912.2015.1040495]
[104]
Rao PV, Gan SH. Cinnamon: a multifaceted medicinal plant. Evid Based Complement Alternat Med 2014.2014642942
[http://dx.doi.org/10.1155/2014/642942] [PMID: 24817901]
[105]
Khader M, Eckl PM. Thymoquinone: an emerging natural drug with a wide range of medical applications. Iran J Basic Med Sci 2014; 17(12): 950-7.
[PMID: 25859298]
[106]
Boukhatem MN. Effective antiviral activity of essential oils and their characteristic terpenes against coronavirus: An update. J Pharmacol Clin Toxicol 2020; 8: 1138.
[107]
Pourghanbari G, Nili H, Moattari A, Mohammadi A, Iraji A. Antiviral activity of the oseltamivir and Melissa officinalis L. essential oil against avian influenza A virus (H9N2). Virusdisease 2016; 27(2): 170-8.
[http://dx.doi.org/10.1007/s13337-016-0321-0] [PMID: 27366768]
[108]
Garozzo A, Timpanaro R, Bisignano B, Furneri PM, Bisignano G, Castro A. In vitro antiviral activity of Melaleuca alternifolia essential oil. Lett Appl Microbiol 2009; 49(6): 806-8.
[http://dx.doi.org/10.1111/j.1472-765X.2009.02740.x] [PMID: 19843207]
[109]
Garozzo A, Timpanaro R, Stivala A, Bisignano G, Castro A. Activity of Melaleuca alternifolia (tea tree) oil on Influenza virus A/PR/8: study on the mechanism of action. Antiviral Res 2011; 89(1): 83-8.
[http://dx.doi.org/10.1016/j.antiviral.2010.11.010] [PMID: 21095205]
[110]
Usachev EV, Pyankov OV, Usacheva OV, Agranovski IE. Antiviral activity of tea tree and eucalyptus oil aerosol and vapour. J Aerosol Sci 2013; 59: 22-30.
[http://dx.doi.org/10.1016/j.jaerosci.2013.01.004]
[111]
Choi H-J. Chemical Constituents of Essential Oils Possessing Anti-Influenza A/WS/33 Virus Activity. Osong Public Health Res Perspect 2018; 9(6): 348-53.
[http://dx.doi.org/10.24171/j.phrp.2018.9.6.09] [PMID: 30584499]
[112]
Vimalanathan S, Hudson J. Anti-influenza virus activity of essential oils and vapors. American Journal of Essential Oils and Natural Products 2014; 2: 47-53.
[113]
Choi Y, Bowman JW, Jung JU. Autophagy during viral infection - a double-edged sword. Nat Rev Microbiol 2018; 16(6): 341-54.
[http://dx.doi.org/10.1038/s41579-018-0003-6] [PMID: 29556036]
[114]
Gassen NC, Niemeyer D, Muth D, et al. SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection. Nat Commun 2019; 10(1): 5770.
[http://dx.doi.org/10.1038/s41467-019-13659-4] [PMID: 31852899]
[115]
Dai JP, Zhao XF, Zeng J, et al. Drug screening for autophagy inhibitors based on the dissociation of Beclin1-Bcl2 complex using BiFC technique and mechanism of eugenol on anti-influenza A virus activity. PLoS One 2013; 8(4)e61026
[http://dx.doi.org/10.1371/journal.pone.0061026] [PMID: 23613775]
[116]
Moy RL, Levenson C. Sandalwood Album Oil as a Botanical Therapeutic in Dermatology. J Clin Aesthet Dermatol 2017; 10(10): 34-9.
[PMID: 29344319]
[117]
Paulpandi M, Kannan S, Thangam R, Kaveri K, Gunasekaran P, Rejeeth C. In vitro anti-viral effect of β-santalol against influenza viral replication. Phytomedicine 2012; 19(3-4): 231-5.
[PMID: 22192867]
[118]
Liao Q, Qian Z, Liu R, An L, Chen X. Germacrone inhibits early stages of influenza virus infection. Antiviral Res 2013; 100(3): 578-88.
[PMID: 24095670]
[119]
Barrero AF, Herrador MM, Arteaga P, Catalán JV. Germacrone: Occurrence, Synthesis, Chemical Transformations and Biological Properties. Nat Prod Commun 2008.
[120]
Hayashi K, Imanishi N, Kashiwayama Y, et al. Inhibitory effect of cinnamaldehyde, derived from Cinnamomi cortex, on the growth of influenza A/PR/8 virus in vitro and in vivo. Antiviral Res 2007; 74(1): 1-8.
[PMID: 17303260]
[121]
Brochot A, Guilbot A, Haddioui L, Roques C. Antibacterial, antifungal, and antiviral effects of three essential oil blends. MicrobiologyOpen 2017; 6(4): 6.
[PMID: 28296357]
[122]
Loizzo MR, Saab A, Tundis R, et al. Phytochemical analysis and in vitro evaluation of the biological activity against herpes simplex virus type 1 (HSV-1) of Cedrus libani A. Rich. Phytomedicine 2008; 15(1-2): 79-83.
[http://dx.doi.org/10.1016/j.phymed.2007.03.013] [PMID: 17482448]
[123]
Ulasli M, Gurses SA, Bayraktar R, et al. The effects of Nigella sativa (Ns), Anthemis hyalina (Ah) and Citrus sinensis (Cs) extracts on the replication of coronavirus and the expression of TRP genes family. Mol Biol Rep 2014; 41(3): 1703-11.
[http://dx.doi.org/10.1007/s11033-014-3019-7] [PMID: 24413991]
[124]
Tisserand R. Essential Oil Safety: A Guide for Health Care Professionals. Churchill Livingstone 1995.
[125]
Silva GL, Luft C, Lunardelli A, et al. Antioxidant, analgesic and anti-inflammatory effects of lavender essential oil. An Acad Bras Cienc 2015; 87(2)(Suppl.): 1397-408.
[http://dx.doi.org/10.1590/0001-3765201520150056] [PMID: 26247152]
[126]
Juergens LJ, Worth H, Juergens UR. New Perspectives for Mucolytic, Anti-inflammatory and Adjunctive Therapy with 1,8-Cineole in COPD and Asthma: Review on the New Therapeutic Approach. Adv Ther 2020; 37(5): 1737-53.
[http://dx.doi.org/10.1007/s12325-020-01279-0] [PMID: 32200535]
[127]
Gandhi GR, Vasconcelos ABS, Haran GH, et al. Essential oils and its bioactive compounds modulating cytokines: A systematic review on anti-asthmatic and immunomodulatory properties. Phytomedicine 2020.73152854
[http://dx.doi.org/10.1016/j.phymed.2019.152854] [PMID: 31036393]
[128]
Lin L, Hu K. Tissue plasminogen activator and inflammation: from phenotype to signaling mechanisms. Am J Clin Exp Immunol 2014; 3(1): 30-6.
[PMID: 24660119]
[129]
Ueno-Iio T, Shibakura M, Yokota K, et al. Lavender essential oil inhalation suppresses allergic airway inflammation and mucous cell hyperplasia in a murine model of asthma. Life Sci 2014; 108(2): 109-15.
[http://dx.doi.org/10.1016/j.lfs.2014.05.018] [PMID: 24909715]
[130]
Huo M, Cui X, Xue J, et al. Anti-inflammatory effects of linalool in RAW 264.7 macrophages and lipopolysaccharide-induced lung injury model. J Surg Res 2013; 180(1): e47-54.
[http://dx.doi.org/10.1016/j.jss.2012.10.050] [PMID: 23228323]
[131]
Cardia GFE, Silva-Filho SE, Silva EL, et al. Effect of Lavender (Lavandula angustifolia) Essential Oil on Acute Inflammatory Response. Evid Based Complement Alternat Med 2018.20181413940
[http://dx.doi.org/10.1155/2018/1413940] [PMID: 29743918]
[132]
Brown S, Garver W, Orlando R. 1,8-cineole: An underappreciated anti-inflammatory therapeutic 2017; 06
[133]
Murakami Y, Kohsaka H, Kitasato H, Akahoshi T. Lipopolysaccharide-induced up-regulation of triggering receptor expressed on myeloid cells-1 expression on macrophages is regulated by endogenous prostaglandin E2. J Immunol 2007; 178(2): 1144-50.
[http://dx.doi.org/10.4049/jimmunol.178.2.1144] [PMID: 17202378]
[134]
Bhaskaran N, Shukla S, Srivastava JK, Gupta S. Chamomile: an anti-inflammatory agent inhibits inducible nitric oxide synthase expression by blocking RelA/p65 activity. Int J Mol Med 2010; 26(6): 935-40.
[PMID: 21042790]
[135]
Zhou E, Fu Y, Wei Z, Yu Y, Zhang X, Yang Z. Thymol attenuates allergic airway inflammation in ovalbumin (OVA)-induced mouse asthma. Fitoterapia 2014; 96: 131-7.
[http://dx.doi.org/10.1016/j.fitote.2014.04.016] [PMID: 24785965]
[136]
Nogueira MNM, Aquino SG, Rossa Junior C. , Spolidorio DMP. Terpinen-4-ol and alpha-terpineol (tea tree oil components) inhibit the production of IL-1β, IL-6 and IL-10 on human macrophages. Inflamm Res 2014; 63(9): 769-78.
[http://dx.doi.org/10.1007/s00011-014-0749-x] [PMID: 24947163]
[137]
ECDPC. European Centre for Disease Prevention and Control (ECDPC) - Worldwide data 2020. Available at: https://www.ecdc.europa.eu/en
[138]
Wen C-C, Kuo Y-H, Jan J-T, et al. Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. J Med Chem 2007; 50(17): 4087-95.
[http://dx.doi.org/10.1021/jm070295s] [PMID: 17663539]

Rights & Permissions Print Cite
Article Metrics
31
2
1
© 2024 Bentham Science Publishers | Privacy Policy